Poly(ADP-Ribose) Polymerase Inhibitor [EPC]

21387 reported adverse events

Drugs of this class: NIRAPARIB OLAPARIB

These side effects are most commonly reported by patients taking drugs of the Poly(ADP-Ribose) Polymerase Inhibitor [EPC] class:

# Side effect Count
0 NAUSEA 4607
1 FATIGUE 3973
2 CONSTIPATION 2835
3 DEATH 2726
4 PLATELET COUNT DECREASED 2715
5 INSOMNIA 1905
6 MALIGNANT NEOPLASM PROGRESSION 1867
7 VOMITING 1690
8 ANAEMIA 1623
9 CARBOHYDRATE ANTIGEN 125 INCREASED 1588
See all common reactions for Poly(ADP-Ribose) Polymerase Inhibitor [EPC]

Drugs of the Poly(ADP-Ribose) Polymerase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CARBOHYDRATE ANTIGEN 125 INCREASED 1588 0.6299
1 EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS 36 0.5455
2 CARBOHYDRATE ANTIGEN 125 8 0.5000
3 BRCA2 GENE MUTATION 19 0.3878
4 OVARIAN CANCER RECURRENT 234 0.3264
5 EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS WORSENED 132 0.2336
6 SCAN ABNORMAL 42 0.1935
7 BRCA1 GENE MUTATION 7 0.1892
8 RECURRENT CANCER 454 0.1795
9 POSITRON EMISSION TOMOGRAM ABNORMAL 63 0.1694
See all enriched reactions for Poly(ADP-Ribose) Polymerase Inhibitor [EPC]